Moroz L V, Donenko F V, Borovkova N B, Sitdikova S M, Kabieva A O
Biull Eksp Biol Med. 1990 Mar;109(3):290-2.
Using hybrid mice BDF1 doxorubicin (Dx) accumulation has been determined in leukemia P388 cells (P388/0), P388 cells with induced resistance to Dx (P388/Dx) and P388 cells with induced resistance to the finoptin (Fp) + Dx combination (P388/Fp + Dx). It has been shown that Fp doesn't affect Dx accumulation in or elimination from leukemia cells P388/0 or P388/Fp + Dx. The resistance of P388/Fp + Dx cells to the Fp + Dx combination develops during 6 passages. It can be concluded that Fp application doesn't abolish the problem of tumor cells' resistance to cytostatics.
利用杂交小鼠,已测定白血病P388细胞(P388/0)、对阿霉素(Dx)诱导耐药的P388细胞(P388/Dx)以及对芬普替丁(Fp)+Dx联合用药诱导耐药的P388细胞(P388/Fp + Dx)中BDF1阿霉素(Dx)的蓄积情况。结果表明,Fp不影响白血病细胞P388/0或P388/Fp + Dx对Dx的摄取或清除。P388/Fp + Dx细胞对Fp + Dx联合用药的耐药性在6次传代过程中形成。可以得出结论,应用Fp并不能消除肿瘤细胞对细胞抑制剂耐药的问题。